本文選題：納米銀粒子 + 膽管支架�。� 參考：《山東中醫(yī)藥大學(xué)》2015年碩士論文

【摘要】：目的:探討化學(xué)氧化還原法制備納米銀粒子涂層膽管支架的可行性,觀察納米銀粒子涂層形態(tài)學(xué)表征和化學(xué)成分穩(wěn)定性。建立梗阻性黃疸比格犬動(dòng)物實(shí)驗(yàn)?zāi)Ｐ?進(jìn)行納米銀粒子涂層膽管支架與普通聚四氟乙烯膽管支架體內(nèi)拮抗支架沉積物對(duì)照實(shí)驗(yàn),為納米銀粒子涂層膽管支架臨床應(yīng)用提供動(dòng)物實(shí)驗(yàn)依據(jù)。方法:實(shí)驗(yàn)共分兩部分。第一部分采用化學(xué)氧化還原法制備納米銀涂層膽管支架,應(yīng)用掃描電鏡、能譜分析檢測(cè)膽管支架納米銀粒子涂層的厚度及化學(xué)成分的穩(wěn)定性。第二部分動(dòng)物實(shí)驗(yàn)。采用12只實(shí)驗(yàn)用健康比格犬為研究對(duì)象,建立梗阻性黃疸動(dòng)物模型后隨機(jī)分為2組,分別行膽管支架置入術(shù)。納米銀涂層膽管支架組(n=6)、普通聚四氟乙烯膽管支架(n=6)。術(shù)后第7,21天分別行實(shí)驗(yàn)室血液白細(xì)胞、肝功檢查,ELISA法檢測(cè)TNF-α、IL-6變化。術(shù)后21天處死實(shí)驗(yàn)動(dòng)物,取出膽管支架和膽管壁組織,分別行:膽管壁組織HE染色病理學(xué)檢查,掃描電鏡(SEM)觀察膽管支架內(nèi)沉積物附著程度;超聲振蕩清除膽管支架沉積物并比較沉積物重量;紅外光譜分析膽管支架內(nèi)沉積物成分;X線能譜儀分析(EDS)觀察術(shù)前術(shù)后納米銀涂層穩(wěn)定性。成果:1.化學(xué)氧化還原法制備納米銀粒子涂層膽管支架,SEM和EDXA觀察納米銀粒子涂層厚度在1.5-6μm之間,銀離子(Ag+)成分單一。2.建立梗阻性黃疸動(dòng)物實(shí)驗(yàn)?zāi)Ｐ?建模前納米銀粒子涂層膽管支架組和Teflon膽管支架組比較,白細(xì)胞(WBC)、谷丙轉(zhuǎn)氨酶(ALT)、谷草轉(zhuǎn)氨酶(AST)、總膽紅素(TBIL)、直接膽紅素(DBIL)水平組間比較差異無統(tǒng)計(jì)學(xué)意義(P0.05);腫瘤壞死因子α(TNF-α)濃度和白細(xì)胞介素6(IL-6)濃度組間比較差異無統(tǒng)計(jì)學(xué)意義(P0.05),各項(xiàng)指標(biāo)符合建模要求。建模后上述2組實(shí)驗(yàn)結(jié)果組間比較同建模前一致。3.動(dòng)物實(shí)驗(yàn)表明,膽管支架置入后,犬梗阻性黃疸模型血液檢查白細(xì)胞、肝功、IL-6、TNF-α較術(shù)均前有明顯下降;納米銀涂層膽管支架組在膽管壁炎癥反應(yīng)程度、支架內(nèi)沉積物厚度、重量方面測(cè)定均優(yōu)于普通膽管支架組;支架內(nèi)沉積物成分含有膽紅素、膽固醇、膽汁酸、膽紅素鈣;EDS檢查術(shù)前、術(shù)后納米銀涂層成分未見明顯差異。結(jié)論:化學(xué)氧化還原法制備膽管支架理化性質(zhì)穩(wěn)定,能滿足納米銀粒子涂層膽管支架動(dòng)物實(shí)驗(yàn)的要求。結(jié)扎比格犬膽總管建立梗阻性黃疸動(dòng)物實(shí)驗(yàn)?zāi)Ｐ?成功率高,能夠滿足納米銀粒子涂層膽管支架拮抗沉積物的實(shí)驗(yàn)要求。納米銀粒子體內(nèi)實(shí)驗(yàn)中,納米銀粒子涂層膽管支架拮抗膽管支架沉積物的效果明顯優(yōu)于普通聚四氟乙烯膽管支架。本課題組將進(jìn)一步進(jìn)行實(shí)驗(yàn)研究,以期盡早將納米銀涂層膽管支架應(yīng)用于臨床。
[Abstract]:Aim: to investigate the feasibility of preparation of silver nanoparticles coated bile duct scaffolds by chemical redox method, and to observe the morphological characterization and chemical composition stability of silver nanoparticles coating. An experimental model of obstructive jaundice was established in Beagle dogs. A control study was conducted between silver nanoparticles coated bile duct scaffolds and common PTFE bile duct stents. To provide the animal experimental basis for the clinical application of silver nanoparticles coated biliary stent. Methods: the experiment was divided into two parts. In the first part, nano-silver coated bile duct scaffolds were prepared by chemical redox method. The thickness of silver nanoparticles coating and the stability of chemical composition were measured by scanning electron microscope and energy dispersive analysis. The second part is animal experiment. Twelve healthy Beagle dogs were used to establish obstructive jaundice model and were randomly divided into two groups. Nano-silver coated bile duct stent group (n = 6), ordinary PTFE bile duct stent (n ~ (6). The changes of TNF- 偽 and IL-6 were detected by Elisa on the 7th day after operation. The experimental animals were killed 21 days after operation. The bile duct stents and bile duct wall tissues were removed. The HE staining and SEM were used to observe the adhesion degree of the bile duct stents. Ultrasonic oscillation was used to remove the stents and the weight of the sediments was compared. The stability of nano-silver coatings before and after operation was observed by infrared spectroscopy (IR) and X-ray energy spectrometer (EDS). Result: 1. SEM and EDXA observation of Silver nanoparticles coated Biliary Stent by Chemical Redox method. The thickness of silver nanoparticles coating is between 1.5-6 渭 m. An animal model of obstructive jaundice was established and compared with Teflon bile duct stent group and nano-silver coated bile duct stent group before modeling. There was no significant difference in WBCU, alt, AST, TBILL, DBIL, TNF- 偽 and IL-6 between the WBC group and the control group (P > 0.05). There was no significant difference between the two groups in the levels of TBILA, TBILL and DBIL. There was no significant difference between the two groups in the concentration of tumor necrosis factor 偽 (TNF- 偽) and interleukin-6 (IL-6). The significance is P0.05, and the indexes meet the requirements of modeling. After modeling, the comparison between the above two groups of experimental results is consistent with that before modeling. 3. 3. Animal experiments showed that the leukocyte and IL-6TNF- 偽 levels in the blood of obstructive jaundice model were significantly decreased after biliary stent implantation, and the degree of inflammation in bile duct wall and the thickness of stents sediment in nano-silver coated bile duct stent group were significantly lower than those before operation. The content of bilirubin, cholesterol, bile acid, calcium bilirubin and calcium bilirubin in the sediments of the stents were better than those in the common bile duct stents before and after EDS examination, there was no significant difference in the composition of the nano-silver coatings after operation. Conclusion: the physical and chemical properties of bile duct scaffolds prepared by chemical redox method are stable and can meet the requirements of nano-silver particles coated bile duct stents. The animal model of obstructive jaundice was established by ligating the common bile duct of Beagle canine. In vivo experiments, silver nanoparticles coated bile duct scaffolds were more effective than conventional PTFE bile duct stents in antagonizing bile duct stents. Further experimental study will be carried out in order to apply nano-silver coated biliary stent to clinic as soon as possible.
【學(xué)位授予單位】：山東中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R657.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉軍樓;許國銘;劉巖;蔡振寨;李兆申;鄒多武;滿曉華;金晶;;放射性塑料膽管支架的實(shí)驗(yàn)研究[J];中華消化雜志;2007年12期

2 劉玉金;楊仁杰;;膽管支架應(yīng)用研究進(jìn)展[J];介入放射學(xué)雜志;2009年04期

3 李秀麗;孔德娟;王梅;劉紅波;;膽管支架的理論研究及臨床應(yīng)用[J];中國組織工程研究與臨床康復(fù);2009年35期

4 蔣雨卉;張俊文;;膽管支架臨床應(yīng)用進(jìn)展[J];醫(yī)學(xué)教育探索;2009年09期

5 李雪;令狐恩強(qiáng);楊云生;李聞;蔡逢春;;放置膽管支架治療膽管梗阻131例臨床分析[J];中國實(shí)用內(nèi)科雜志;2008年04期

6 王成;黃強(qiáng);胡圓國;邱陸軍;陳炯;查恕云;;經(jīng)內(nèi)鏡膽管支架置放技術(shù)相關(guān)問題探討[J];肝膽胰外科雜志;2008年05期

7 陳新娣;溫素蓮;;內(nèi)鏡下膽管支架內(nèi)引流術(shù)的護(hù)理體會(huì)[J];現(xiàn)代消化及介入診療;2009年02期

8 李兆申;正確掌握內(nèi)鏡下膽管支架引流適應(yīng)癥[J];肝膽外科雜志;2005年03期

9 楊恩成;;帶膜和無膜金屬膽管支架治療惡性膽梗阻的阻塞情況分析[J];黑龍江醫(yī)學(xué);2010年01期

10 張戈;楊成俊;張麗;;經(jīng)內(nèi)鏡膽管支架置入在十二指腸壺腹周圍癌腫的臨床應(yīng)用[J];兵團(tuán)醫(yī)學(xué);2011年01期

相關(guān)會(huì)議論文 前1條

1 劉錦華;潘勝武;張麗萍;宋雙紅;;膽管支架治療膽管良惡性梗阻78例的護(hù)理體會(huì)[A];中華醫(yī)學(xué)會(huì)第七次全國消化病學(xué)術(shù)會(huì)議論文匯編（下冊(cè)）[C];2007年

相關(guān)碩士學(xué)位論文 前2條

1 夏明峰;納米銀涂層膽管支架與普通聚四氟乙烯膽管支架拮抗支架阻塞沉積物的對(duì)照實(shí)驗(yàn)研究[D];山東中醫(yī)藥大學(xué);2015年

2 郭會(huì)娟;磺酸根離子化及白蛋白預(yù)吸附對(duì)膽管支架細(xì)菌吸附影響的體外研究[D];新鄉(xiāng)醫(yī)學(xué)院;2014年

，

本文編號(hào)：2012081